Pharma-Bio Serv, Inc. (PBSV) stock
PBSVOTCServices-Management Consulting ServicesFiscal year ends October 31
$0.48+0.08 (+20.00%)
Close on Oct 19, 2026Market cap $11.00MP/E 48.0Yield –
Pharma-Bio Serv EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Pharma-Bio Serv's EPS for the twelve months ending Jul 31, 2026 was $0.01. For fiscal 2025 it was -$0.00. The highest annual figure on record is $0.21 in fiscal 2013.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -$0.00 | – |
| FY2024 | Oct 31, 2024 | -$0.03 | -159.6% |
| FY2023 | Oct 31, 2023 | $0.06 | -36.0% |
| FY2020 | Oct 31, 2020 | $0.09 | -1.1% |
| FY2019 | Oct 31, 2019 | $0.09 | – |
| FY2017 | Oct 31, 2017 | -$0.06 | – |
| FY2016 | Oct 31, 2016 | -$0.01 | -115.9% |
| FY2015 | Oct 31, 2015 | $0.07 | -32.4% |
| FY2014 | Oct 31, 2014 | $0.10 | -50.7% |
| FY2013 | Oct 31, 2013 | $0.21 | +1.5% |
| FY2012 | Oct 31, 2012 | $0.20 | +45.7% |
| FY2011 | Oct 31, 2011 | $0.14 | +723.5% |
| FY2010 | Oct 31, 2010 | $0.02 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | -$0.00 | – |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | $0.01 | +150.0% |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | $0.00 | – |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | $0.00 | – |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -$0.01 | -164.3% |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | $0.00 | – |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | $0.00 | – |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | $0.00 | – |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | $0.01 | -30.0% |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -$0.01 | -145.0% |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | -$0.01 | -160.0% |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | $0.00 | -100.0% |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | $0.02 | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | $0.02 | – |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | $0.02 | -80.0% |
| Q1 FY2022CQ4 2021 | Jul 31, 2022 | $0.04 | +300.0% |
| Q2 FY2022CQ1 2022 | Apr 30, 2022 | -$0.01 | -200.0% |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | -$0.21 | -2200.0% |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | $0.10 | +233.3% |
| Q2 FY2021CQ1 2021 | Apr 30, 2021 | $0.01 | -66.7% |
| Q1 FY2021CQ4 2020 | Jan 31, 2021 | $0.01 | -50.0% |
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | $0.01 | -50.0% |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | $0.03 | +50.0% |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | $0.03 | 0.0% |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | $0.02 | 0.0% |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | $0.02 | -85.7% |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | $0.02 | -37.5% |
| Q2 FY2019CQ1 2019 | Apr 30, 2019 | $0.03 | – |
| Q1 FY2019CQ4 2018 | Jan 31, 2019 | $0.02 | – |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | $0.14 | – |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | $0.03 | – |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | -$0.01 | – |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | -$0.12 | – |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | -$0.02 | – |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | -$0.01 | – |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | -$0.01 | – |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | -$0.02 | – |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | -$0.02 | – |
| Q3 FY2016CQ2 2016 | Jul 31, 2016 | -$0.01 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?